Journal: PLoS ONE

Article Title: Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay

doi: 10.1371/journal.pone.0221123

Figure Lengend Snippet: Comparison of BRAF and NRAS results by allele specific amplification, Sanger sequencing, IHC and Idylla testing.

Article Snippet: Slides were stained with anti-BRAF V600E mutant-specific antibody (clone VE1, dilution 1:200, pH9, Eurobio) [ ] .

Techniques: Comparison, Amplification, Sequencing, Mutagenesis

Journal: PLoS ONE

Article Title: Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay

doi: 10.1371/journal.pone.0221123

Figure Lengend Snippet: A. Control of samples found positive for BRAF mutation by ASA/Sequencing but negative by IHC. B. Control of samples found negative for BRAF mutation by ASA/sequencing and positive by IHC (wrong chromogen used). C. Control of samples found positive for NRAS mutation by sequencing but negative by Idylla. Yellow dots correspond to wild type DNA copies ( BRAF , panels A and B; NRAS , panel C). Green dots correspond to mutated DNA copies ( BRAF V600E, panels A and B; NRAS Q61R, panel C). Grey dots correspond to empty wells.

Article Snippet: Slides were stained with anti-BRAF V600E mutant-specific antibody (clone VE1, dilution 1:200, pH9, Eurobio) [ ] .

Techniques: Control, Mutagenesis, Sequencing

Journal: PLoS ONE

Article Title: Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay

doi: 10.1371/journal.pone.0221123

Figure Lengend Snippet: Discordant genotyping results.

Article Snippet: Slides were stained with anti-BRAF V600E mutant-specific antibody (clone VE1, dilution 1:200, pH9, Eurobio) [ ] .

Techniques: Digital PCR

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Population-based screening for BRAF V600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis

doi: 10.1158/1078-0432.CCR-20-1024

Figure Lengend Snippet: Kaplan-Meier estimation of overall survival of patients with mCRC and BRAFV600E mutations detected by IHC (BRAFIHC) and NGS (BRAFNGS).

Article Snippet: BRAF Immunohistochemistry: Within VCH, BRAF V600E mutation status was determined by mutation-specific IHC (VE1 antibody, Spring Bioscience) with on-slide control as previously described 9 .

Techniques:

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Population-based screening for BRAF V600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis

doi: 10.1158/1078-0432.CCR-20-1024

Figure Lengend Snippet: Multivariate analysis of impact of patient characteristics on overall survival of metastatic colorectal cancer patients.

Article Snippet: BRAF Immunohistochemistry: Within VCH, BRAF V600E mutation status was determined by mutation-specific IHC (VE1 antibody, Spring Bioscience) with on-slide control as previously described 9 .

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma

doi: 10.3390/jcm9123830

Figure Lengend Snippet: Clinicopathological parameters in different thyroid cancers.

Article Snippet: IHC using anti-TUBB3 (TUJ1, 1:200; Covance, Princeton, NJ, USA), anti-E-cadherin (ECAD; HECD-1, 1:100; abcam, Cambridge, UK) antibodies, and BRAF-mutation-specific antibody (VE1, 1:100; Spring Bioscience, Pleasanton, CA, USA) was performed according to the validated protocols using an automated immunostainer (Ventana, Tuscon, AZ, USA).

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma

doi: 10.3390/jcm9123830

Figure Lengend Snippet: TUBB3 and E-cadherin expression in thyroid cancer. ( A – D ) TUBB3. ( A , B ) cPTC. (A) A low-power view of cPTC revealed TUBB3-positive tumor cells located at the invasive margin. ( B ) A high-power view showed strong TUBB3 expression in both stromal cells and tumor cells at the invasive front. ( C ) In EFVPTC, only a few scattered TUBB3-positive tumor cells were observed. Stromal cells were negative for TUBB3 in this case. ( D ) Tumor cells of ATC were strongly positive for TUBB3 in a diffuse pattern. ( E – G ) E-cadherin. ( E ) In cPTC, some tumor cells at the periphery showed loss of E-cadherin expression (arrows) while tumor cells at the center retained membranous E-cadherin expression. ( F ) Tumor cells in EFVPTC generally maintained membranous E-cadherin expression. ( G ) ATC tumor cells showed loss of E-cadherin expression throughout the tumor.

Article Snippet: IHC using anti-TUBB3 (TUJ1, 1:200; Covance, Princeton, NJ, USA), anti-E-cadherin (ECAD; HECD-1, 1:100; abcam, Cambridge, UK) antibodies, and BRAF-mutation-specific antibody (VE1, 1:100; Spring Bioscience, Pleasanton, CA, USA) was performed according to the validated protocols using an automated immunostainer (Ventana, Tuscon, AZ, USA).

Techniques: Expressing

Journal: Journal of Clinical Medicine

Article Title: Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma

doi: 10.3390/jcm9123830

Figure Lengend Snippet: Differences of TUBB3 and E-cadherin expression and tumor budding among thyroid cancers. ( A ) TUBB3 H-score was highest in ATC, followed by cPTC, infiltrative FVPTC, invEFVPTC, and NIFTP. ( B ) High stromal TUBB3 expression was more common in cPTC and ATC than in invEFVPTC and NIFTP. ( C ) The proportion of tumor cells showing loss of E-cadherin expression, which was also highest in ATC, followed by cPTC, infiltrative FVPTC, invEFVPTC, and NIFTP. ( D ) Tumor budding was more commonly observed in cPTC and infiltrative FVPTC than in EFVPTC. cPTC; conventional papillary thyroid carcinoma, FVPTC; follicular variant papillary carcinoma, invEFVPTC; invasive encapsulated follicular variant papillary carcinoma, NIFTP; non-invasive follicular thyroid tumors with papillary-like nuclear features, ATC; anaplastic thyroid carcinoma.

Article Snippet: IHC using anti-TUBB3 (TUJ1, 1:200; Covance, Princeton, NJ, USA), anti-E-cadherin (ECAD; HECD-1, 1:100; abcam, Cambridge, UK) antibodies, and BRAF-mutation-specific antibody (VE1, 1:100; Spring Bioscience, Pleasanton, CA, USA) was performed according to the validated protocols using an automated immunostainer (Ventana, Tuscon, AZ, USA).

Techniques: Expressing, Variant Assay

Journal: Journal of Clinical Medicine

Article Title: Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma

doi: 10.3390/jcm9123830

Figure Lengend Snippet: Differential TUBB3 and E-cadherin expression among thyroid cancers.

Article Snippet: IHC using anti-TUBB3 (TUJ1, 1:200; Covance, Princeton, NJ, USA), anti-E-cadherin (ECAD; HECD-1, 1:100; abcam, Cambridge, UK) antibodies, and BRAF-mutation-specific antibody (VE1, 1:100; Spring Bioscience, Pleasanton, CA, USA) was performed according to the validated protocols using an automated immunostainer (Ventana, Tuscon, AZ, USA).

Techniques: Expressing

Journal: Journal of Clinical Medicine

Article Title: Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma

doi: 10.3390/jcm9123830

Figure Lengend Snippet: Tumor budding in cPTC. ( A ) A high magnification view showed cPTC with a single tumor cell or small clusters of tumor cells in fibrotic stroma at the periphery (×400). ( B ) These tumor buddings were positive for cytokeratin immunohistochemistry (×400). ( C ) Membranous E-cadherin expression was lost in some of these cells (×400).

Article Snippet: IHC using anti-TUBB3 (TUJ1, 1:200; Covance, Princeton, NJ, USA), anti-E-cadherin (ECAD; HECD-1, 1:100; abcam, Cambridge, UK) antibodies, and BRAF-mutation-specific antibody (VE1, 1:100; Spring Bioscience, Pleasanton, CA, USA) was performed according to the validated protocols using an automated immunostainer (Ventana, Tuscon, AZ, USA).

Techniques: Immunohistochemistry, Expressing

Journal: Journal of Clinical Medicine

Article Title: Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma

doi: 10.3390/jcm9123830

Figure Lengend Snippet: Transwell invasion assay and shRNA transfection. ( A , C ) Immunofluorescent and ( B , D ) Giemsa staining revealed reduced invasion activity of ATC cells after shRNA transfection. ( E ) Western blot revealed increased vimentin and TUBB3 expression and decreased E-cadherin expression after transwell invasion compared with baseline. ( G ) RT-PCR also revealed increased TUBB3 expression after transwell invasion. ( F ) Western blot after shRNA transfection showed decreased vimentin and TUBB3 expression and increased E-cadherin expression compared with baseline. ( H ) RT-PCR also revealed decreased TUBB3 expression after shRNA transfection.

Article Snippet: IHC using anti-TUBB3 (TUJ1, 1:200; Covance, Princeton, NJ, USA), anti-E-cadherin (ECAD; HECD-1, 1:100; abcam, Cambridge, UK) antibodies, and BRAF-mutation-specific antibody (VE1, 1:100; Spring Bioscience, Pleasanton, CA, USA) was performed according to the validated protocols using an automated immunostainer (Ventana, Tuscon, AZ, USA).

Techniques: Transwell Invasion Assay, shRNA, Transfection, Staining, Activity Assay, Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction

Journal: Journal of Clinical Medicine

Article Title: Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma

doi: 10.3390/jcm9123830

Figure Lengend Snippet: Survival analysis in conventional papillary thyroid carcinoma.

Article Snippet: IHC using anti-TUBB3 (TUJ1, 1:200; Covance, Princeton, NJ, USA), anti-E-cadherin (ECAD; HECD-1, 1:100; abcam, Cambridge, UK) antibodies, and BRAF-mutation-specific antibody (VE1, 1:100; Spring Bioscience, Pleasanton, CA, USA) was performed according to the validated protocols using an automated immunostainer (Ventana, Tuscon, AZ, USA).

Techniques: